- Home
- OLP vs AUTL Comparison
OLP vs AUTL Comparison
Compare OLP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | AUTL |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United Kingdom |
| Employees | 9 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 596.2M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | OLP | AUTL |
|---|---|---|
| Price | $22.82 | $1.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.75 | $8.50 |
| AVG Volume (30 Days) | 52.4K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $82,740,000.00 | $10,120,000.00 |
| Revenue This Year | $11.98 | $80.32 |
| Revenue Next Year | $3.71 | $53.96 |
| P/E Ratio | $22.96 | ★ N/A |
| Revenue Growth | 1.02 | ★ 496.00 |
| 52 Week Low | $19.62 | $1.18 |
| 52 Week High | $25.88 | $2.58 |
Technical Indicators
Market Signals| Indicator | OLP | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 30.63 | 41.51 |
| Support Level | $22.36 | $1.37 |
| Resistance Level | $23.63 | $1.92 |
| Average True Range (ATR) | 0.43 | 0.09 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 16.40 | 13.76 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.